Literature DB >> 3383424

Lactate dehydrogenase M-subunit deficiency: a new type of hereditary exertional myopathy.

T Kanno1, K Sudo, M Maekawa, Y Nishimura, M Ukita, K Fukutake.   

Abstract

Three families with a complete deficiency of the lactate dehydrogenase M subunit show exertional myoglobinuria. The response to ischemic forearm work is characteristic in these three families: an increase of venous lactate concentration after ischemic work was not observed and a marked increase of venous pyruvate was found. Glycolysis was markedly retarded in the patient's muscle in the glyceraldehyde 3-phosphate dehydrogenase (GA3PD) step. A significant increases in glyceraldehyde 3-phosphate, dihydroxyacetone phosphate and fructose 1,6-diphosphate were observed. The glycolysis retardation may be attributed to the impaired reoxidation of NADH produced by GA3PD action. The cytosolic fraction of skeletal muscle is rich in alpha-glycerophosphate dehydrogenase. This enzyme reoxidizes the excess NADH and drains triose phosphates from the glycolytic pathway under anaerobic conditions. For this reason, ATP production was significantly impaired and muscle cells were damaged in these patients. Consequently, the cytosolic enzymes and proteins such as creatine kinase and myoglobin were released into the blood stream. Otherwise, patients with a lactate dehydrogenase M-subunit deficiency do not show muscle stiffness and myoglobinuria under ordinary circumstances. They complain of muscle rigidity and sudden myoglobinuria after strenous exercise under anaerobic conditions. Thus, the lactate dehydrogenase M-subunit deficiency does not show any symptoms under ordinary circumstances, but is a latent hereditary disorder, now recognized as a new type of hereditary exertional myoglobinuria.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3383424     DOI: 10.1016/0009-8981(88)90359-2

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  41 in total

Review 1.  Targeting lactate metabolism for cancer therapeutics.

Authors:  Joanne R Doherty; John L Cleveland
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 2.  Myopathies Related to Glycogen Metabolism Disorders.

Authors:  Mark A Tarnopolsky
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 3.  Metabolic Myoglobinuria.

Authors:  Emanuele Barca; Valentina Emmanuele; Salvatore Billi DiMauro
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

4.  Molecular Pathways: Targeting Cellular Energy Metabolism in Cancer via Inhibition of SLC2A1 and LDHA.

Authors:  Aik T Ooi; Brigitte N Gomperts
Journal:  Clin Cancer Res       Date:  2015-04-02       Impact factor: 12.531

Review 5.  Small-molecule inhibitors of human LDH5.

Authors:  Carlotta Granchi; Ilaria Paterni; Reshma Rani; Filippo Minutolo
Journal:  Future Med Chem       Date:  2013-10       Impact factor: 3.808

6.  Genotypic analysis of families with lactate dehydrogenase A (M) deficiency by selective DNA amplification.

Authors:  M Maekawa; K Sudo; S S Li; T Kanno
Journal:  Hum Genet       Date:  1991-11       Impact factor: 4.132

7.  Molecular characterization of genetic mutations in human lactate dehydrogenase (LDH) B (H) variant.

Authors:  K Sudo; M Maekawa; A Tomonaga; T Tsukada; T Nakayama; M Kitamura; S S Li; T Kanno; J Toriumi
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

8.  Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis.

Authors:  Joanne R Doherty; Chunying Yang; Kristen E N Scott; Michael D Cameron; Mohammad Fallahi; Weimin Li; Mark A Hall; Antonio L Amelio; Jitendra K Mishra; Fangzheng Li; Mariola Tortosa; Heide Marika Genau; Robert J Rounbehler; Yunqi Lu; Chi V Dang; K Ganesh Kumar; Andrew A Butler; Thomas D Bannister; Andrea T Hooper; Keziban Unsal-Kacmaz; William R Roush; John L Cleveland
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

9.  LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.

Authors:  Han Xie; Vladimir A Valera; Maria J Merino; Angela M Amato; Sabina Signoretti; William M Linehan; Vikas P Sukhatme; Pankaj Seth
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

10.  A mutation affecting the lactate dehydrogenase locus Ldh-1 in the mouse. II. Mechanism of the LDH-A deficiency associated with hemolytic anemia.

Authors:  W Pretsch; S Merkle; J Favor; T Werner
Journal:  Genetics       Date:  1993-09       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.